News & Updates

The leading cause of disease burden and death across the globe is still cardiovascular disease (CVD), with low, low-middle, and middle sociodemographic index (SDI) regions carrying the heaviest burden, according to a study.

In the phase III ICONIC-LEAD trial, selective blockade of the interleukin(IL)-23 receptor with the targeted oral peptide icotrokinra is associated with higher rates of skin clearance and symptom relief in adults and adolescents with moderate-to-severe plaque psoriasis.